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Improving quality of life has been recognized as an important outcome for schizophrenia
treatment, although the fundamental determinants are not well understood. In this study, we
investigated the association between brain structural abnormalities and objective quality of
life in schizophrenia patients. Thirty-three schizophrenia patients and 42 age-, sex-, and
education-matched healthy participants underwent magnetic resonance imaging. The Qual-
ity of Life Scale was used to measure objective quality of life in schizophrenia patients.
Voxel-based morphometry was performed to identify regional brain alterations that correlate
with Quality of Life Scale score in the patient group. Schizophrenia patients showed gray
matter reductions in the frontal, temporal, limbic, and subcortical regions. We then per-
formed voxel-based multiple regression analysis in these regions to identify any correlations
between regional gray matter volume and Quality of Life Scale scores. We found that
among four subcategories of the scale, the Instrumental Role category score correlated
with gray matter volume in the right anterior insula in schizophrenia patients. In addition, this
correlation was shown to be mediated by negative symptoms. Our findings suggest that the
neural basis of objective quality of life might differ topographically from that of subjective
QOL in schizophrenia.
Introduction
Improving quality of life (QOL) is considered a crucial factor in the treatment of schizophrenia
[1]. Factors associated with QOL in schizophrenia, and which can serve as predictors of QOL,
include depressive symptoms [2–4], adverse drug effects [5], cognitive dysfunction [6–9], occu-
pation [10], and positive [11, 12] and negative symptoms [6, 11, 13–16], in schizophrenia.
Nevertheless, there are several inconsistencies in the results on factors influencing QOL in
schizophrenia patients [17]. While some studies report weak to moderate relationships
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between psychiatric positive/negative symptoms and QOL [18, 19], other studies suggest that it
is difficult to determine if positive/negative symptoms have significant influences on QOL [4,
11]. This inconsistency may be attributable to there being two aspects of QOL i.e., subjective
and objective QOLs [6, 13, 16]. Levels of objective and subjective QOL can differ because each
may be influenced by different factors: it was reported that subjective QOL might be influenced
by depression [20], insight into the illness [21], and positive symptoms [11, 22], whereas objec-
tive QOL might be determined by cognitive function [23] and negative symptoms [11]. This
dichotomy is simple and seems reasonable, although we need to bear in mind that the results
are still controversial: for example, subjective QOL in schizophrenia is also reported to be sig-
nificantly associated with negative symptoms and poor cognitive functioning [24].
Schizophrenia patients have gray matter (GM) volume reductions in specific brain regions
including the insula, anterior cingulate cortex, inferior and medial frontal gyrus, hippocampus,
amygdala, and thalamus [25–28]. Furthermore, some of these regional GM alterations are
related to symptom severity in schizophrenia patients. For example, a large sample voxel-based
morphometry (VBM) study reported correlation between volume reduction in the perisylvian
region and positive symptoms [29]. Similarly, a multimodal voxelwise meta-analysis of neuro-
anatomical abnormalities in schizophrenia reported a significant relationship between negative
symptoms and abnormalities in the medial frontal gyrus/orbitofrontal cortex/insula [25]. How-
ever, with few exceptions, little research has been performed on the neural basis impacting
QOL in schizophrenia. One such study is our previous report, which found association
between regional brain volume in the dorsolateral prefrontal cortex (DLPFC) and subjective
QOL in schizophrenia, which is mediated by positive symptoms [12].
In consideration of this report [12], here we investigated the relationship between objective
QOL, and GM alterations with an aim to illustrate the contrast of neural basis of subjective and
objective QOLs in schizophrenia patients. We hypothesized that objective QOL in schizophre-
nia might be related to brain morphological changes, and that such a relation might be partly
mediated by clinical symptoms. We also predicted that the brain regions which were related to
objective and subjective QOLs may topographically differ, and that the relationships would be
mediated by different psychopathology in the two QOLs. Consequently, we first examined
regional brain alterations in schizophrenia that showed significant correlation with levels of
objective QOL. We then examined how clinical symptoms mediate this relationship.
Materials and Methods
Participants
The schizophrenia group comprised 33 patients (14 female; mean age 35.7, S.D. 9.4) referred to
the Department of Psychiatry, Kyoto University Hospital (Kyoto, Japan). Each patient fulfilled
the criteria for schizophrenia based on the Structured Clinical Interview for Diagnostic and
Statistical Manual of Mental Disorders, 4th edition (DSM-IV), patient edition (SCID-I/P) [30].
A patients’ competence to consent was confirmed by the psychiatrist in charge and double-
checked by board certified senior consultant psychiatrists. Clinical symptoms were assessed
using the Positive and Negative Syndrome Scale (PANSS) [31]. All patients were taking anti-
psychotic medication (first-generation [N = 3], second-generation [N = 24], or first and second
generation [N = 6]). The medication dosage on the day of scanning was converted to haloperi-
dol equivalent, according to the practice guidelines for the treatment of patients with schizo-
phrenia [32, 33]. Participants were all physically healthy at the time of scanning. None had a
history of neurological injury or disease, severe medical illness, or substance abuse that may
affect brain structure and function. The comparison group comprised 42 healthy individuals
(21 female; mean age 36, S.D. 7.6) that were matched to the schizophrenia group with respect
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to age, sex, and education level. They were also evaluated using SCID to confirm that they had
no history of neurological or psychiatric disease, and no first-degree relatives had a history of
psychotic episodes. Vocabulary and block design subtests from the Wechsler Adult Intelligence
Scale-Revised [34] were used to estimate verbal IQ (VIQ) and performance IQ (PIQ), respec-
tively, by transforming age-corrected scores into T-scores. The demographic and clinical data
are summarized in Table 1. All of the patients participated our previous study [12]. This study
was approved by the Committee on Medical Ethics of Kyoto University, and performed in
accordance with The Code of Ethics of the World Medical Association. After a complete
description of the study, each participant provided written informed consent.
Quality of Life Scale, Japanese version (QLS)
The Quality of Life Scale (QLS), an observer-rated 21-item questionnaire, was used to assess
objective QOL in schizophrenia patients [35]. Because of good reliability and validity, the scale
has been widely used previously in patients with schizophrenia [1, 6, 23]. The scale is composed
of four categories: (1) Intrapsychic Foundations (IF)–clinical judgment on intrapsychic ele-
ments in the dimensions of cognition, conation, and affectivity; (2) Interpersonal Relations
(IP)–various aspects of interpersonal and social experience; (3) Instrumental Role (IR)–judg-
ments on level of accomplishment and degree of underemployment, given the person’s talents
and opportunities, and satisfaction; and (4) Common Objects and Activities (OA)–possession
of common objects and engagement in a range of regular activities. Each item is rated on a
Table 1. Demographic and clinical characteristics of subjects.
HC (N = 42) SC (N = 33) Statistics
Mean S.D. Mean S.D. t p
Age (years) 36 7.6 35.7 9.4 - 0.32 n.s
Sex (male / female) 21 / 21 - 19 / 24 0.13 n.s
Handedness (left / right) 3 / 39 - 3 / 30
Education level 13.8 2.5 13.7 2.5 - 0.29 n.s
VIQ 106.6 18.4 100.5 18.3 1.43 n.s
PIQ 114.3 14.8 105.3 18.3 2.54 0.01*
Duration of illness (months) 110.5 15.8
Drug (mg / day, HPD equivalent)a 11.8 8.1
PANSS Positive 14.0 5.7
PANSS Negative 16.1 5.7
QLS Interpersonal relations 23.8 9.3
QLS Instrumental role 9.6 5.4
QLS Intrapsychic foundations 23.9 8.5
QLS Common objects and activities 8.0 1.6
JSQLS Psychosocial 45.0 19.0
JSQLS Motivation / energy 52.4 11.8
JSQLS Symptom / side effect 25.3 18.4
Abbreviations: SC, schizophrenia patients; HC, healthy controls; PANSS, Positive and Negative Syndrome Scale; VIQ, estimated verbal IQ obtained from
the vocabulary subtask in the Wechsler Adult Intelligence Scale-Revised (WAIS-R) by transforming age-corrected scores into T-scores; PIQ, estimated
performance IQ obtained from the block design subtask in the WAIS-R by transforming age-corrected scores into T-scores; QLS = The Quality of Life
Scale; SQLS = Schizophrenia Quality of Life Scale.
a Haloperidol equivalent was calculated according to Inagaki and Inada [32]
* two-sample t-test (p < 0.05).
doi:10.1371/journal.pone.0142018.t001
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seven-point Likert scale ranging from 0 “severe impairment of function” to 6 “normal or unim-
paired functioning”. Thus, higher scores indicate higher levels of objective QOL. All data were
obtained from semi-structured interviews by a trained clinician. The standardized Japanese
version of QLS was used [36].
Schizophrenia Quality of Life Scale, Japanese version (JSQLS)
The Japanese version of the Schizophrenia Quality of Life Scale (JSQLS) [37, 38] was used to
assess subjective QOL of schizophrenia patients. It is a self-report 30-item questionnaire for
measuring QOL specific to patients with schizophrenia. The scale is composed of three sub-
scales: (1) psychosocial, (2) motivation/energy, and (3) symptoms/side-effects. Each of the
thirty items is rated on a five-point Likert scale ranging from 0 “strongly disagree” to 4
“strongly agree”, and lower scores indicate higher levels of subjective QOL.
MRI acquisition and pre-processing
All participants underwent magnetic resonance imaging (MRI) scans on a 3-Tesla whole-body
scanner with a 40-mT/m gradient and a receiver-only 8-channel phased-array head coil (Trio,
Siemens, Erlangen, Germany). The scanning parameters for three-dimensional magnetization-
prepared rapid gradient-echo (3D-MPRAGE) sequences were: repetition time (TR) = 2000 ms,
echo time (TE) = 4.38 ms, T1 = 990 ms, field-of-view (FOV) = 225 × 240 mm, matrix = 240
×256, resolution = 0.9375 × 0.9375 × 1.0 mm, and 208 total axial sections without intersection
gaps. MRI data were processed and analyzed using statistical parametric mapping software
(SPM8; Welcome Department of Imaging Neuroscience, London, UK), with the VBM8
toolbox (http://dbm.neuro.uni-jena.de/vbm) running in Matlab 2014b (MathWorks, Natick,
MA, USA). All images were tissue classified and spatially normalized to the same stereotaxic
space using the diffeomorphic anatomical registration through the exponentiated Lie algebra
(DARTEL) algorithm [39]. Output images of GM, white matter, and cerebrospinal fluid seg-
ment partitions were resliced into 1 × 1 × 1 mm voxels. Voxel values from segmented and nor-
malized GM images were multiplied (modulated) by Jacobian determinants obtained from
non-linear normalization steps. The resultant GM images were smoothed using Gaussian ker-
nels of 6 mm full width at half maximum, on which all analyses were performed.
Data analyses
Regional GM reductions in patients relative to controls. To identify brain regions in
which schizophrenia patients showed GM volume reductions compared with controls, two-
sample t-tests were performed in SPM8. The effects of age and gender were excluded. A statisti-
cal threshold of p< 0.001 (uncorrected) with an extent threshold of 20 voxels was applied [40].
The resultant image was used as an inclusion mask for the following correlational analyses.
Correlation of QLS scores with GM volume. To identify brain regions where GM volume
reductions in schizophrenia correlate with QLS category scores, multiple regression analyses
were performed in SPM8, with age and gender as nuisance covariates. In addition, further anal-
yses were performed. First, with a statistical threshold of p< 0.001 (uncorrected) and an extent
threshold of 20 voxels, each participant’s GM volume data for significant clusters (eigenvari-
ates) was extracted using the Volume-Of-Interest (VOI) function in SPM8. Second, partial cor-
relation analysis between extracted GM volume data and each QLS category score was
performed using SPSS 22 (IBM Co., Armonk, NY, USA), controlling for the effects of educa-
tion, IQ, illness duration, antipsychotic medication dosage at time of scanning, and positive/
negative symptoms of PANSS. Statistical significance was set at p< 0.05. To estimate the medi-
ation effect of clinical symptoms on the relationship between GM volume and objective QOL,
Insular GMV and Objective QOL in Schizophrenia
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a multiple mediation analysis [41] was performed for PANSS negative and positive scores
using the INDIRECT macro for SPSS [42]. Standardized coefficients between GM volume and
QLS category scores in the bivariate analysis (i.e., total effect, c coefficient) and mediation anal-
ysis (i.e., direct effect, c0 coefficient), their 95% confidence intervals, and the differences
between c and c0 were calculated based on 1000 bootstrap samples. In these analyses, QLS cate-
gory scores were included as dependent variables, extracted GM volume data as independent
variables, and each positive and negative score as mediator variables. Because of the relatively
small sample size and exploratory nature of this study, multiple comparison corrections were
not performed across clusters and category scores of QLS and PANSS positive/negative scores.
Uncorrected p-values of 0.05 were regarded as the statistical threshold for significance in all
correlational analyses.
Correlational analyses between QLS and SQLS
We conducted correlational analyses between each of the QLS subcategory scores and each of
SQLS subscores.
Results
Demographic and clinical data
Table 1 shows demographic and clinical information. There were no significant differences
between patients and controls in any demographics (age, gender, handedness, and education
level), except for estimated PIQ (p = 0.01).
Regional GM reductions in patients relative to controls
In agreement with previous studies [25–28], schizophrenia patients showed GM reductions
compared with controls in areas containing regions such as the bilateral inferior frontal gyrus,
middle frontal gyrus, superior frontal gyrus, temporal gyrus, thalamus, and insula (Fig 1).
Correlation analyses for GM volume and QLS category scores
Multiple regression analyses found that IR score positively correlated with right anterior insula
(AI) GM volume (peak coordinates: x, y, z = 34, 32, −5 cluster size = 33 voxels) in the patient
group (Fig 2). None of the other QLS category scores significantly correlated with GM volume.
Correlation between IR category score and extracted right AI volume remained significant
after controlling for all demographic and clinical variables (Table 2). A specific, significant
mediation effect was observed for PANSS negative score (bias corrected 95% confidence inter-
val = 4.19–147 by 1000 bootstrap resamples) between right AI GM volume and IR score (Fig
3). The mediation effect was not significant for positive symptoms (bias corrected 95% confi-
dence intervals = −0.68–78.9 by 1000 bootstrap resamples) (Fig 4).
Correlational analyses between QLS and JSQLS. Correlational analyses found that sev-
eral JSQLS subscores were significantly correlated with subscales of objective QOL (Table 3).
However, we found no correlation between each of JSQLS subscale score and IR score.
Discussion
To our knowledge, this is the first study to investigate the relationship between objective QOL,
symptoms, and regional brain volume in schizophrenia patients. We found a significant corre-
lation between right AI volume and objective QOL in schizophrenia patients. Furthermore,
this correlation was mediated by negative symptoms, but not positive symptoms. These find-
ings suggest that reduced GM volume in the right AI is linked to poor objective QOL in
Insular GMV and Objective QOL in Schizophrenia
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Fig 2. Multiple regression analysis using voxel-basedmorphometry to identify the brain region that
significantly correlates with QLS Instrumental Role score. The white cluster on the right AI (x = 34,
y = 32, z = −5; cluster size = 33) significantly correlates with QLS Instrumental Role score. The color bar
represents the T-score: white indicates higher statistical significance than yellow or red. Uncorrected
p < 0.001; extent threshold 20 voxels.
doi:10.1371/journal.pone.0142018.g002
Fig 1. Group difference in gray matter volume. Yellow clusters reflect gray matter reductions in the inferior
frontal gyrus, middle frontal gyrus, superior frontal gyrus and insula in schizophrenia patients compared with
healthy controls. The color bar represents the T-score: white indicates higher statistical significance than
yellow or red. Uncorrected p < 0.001; extent threshold 20 voxels.
doi:10.1371/journal.pone.0142018.g001
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schizophrenia, and can be partially explained by negative symptoms. Our exploratory study
implies that a combination of imaging and psychosocial assessments would be useful to deter-
mine the factors affecting QOL in schizophrenia.
In the patient group, right AI volume correlated with IR score, a subscale that measures suf-
ficiency for an occupational role in social life. This correlation was not diminished even after
controlling for clinical score. The insula is a brain region related to emotional processing and
sensory stimuli. Within the insula, the anterior part is involved in emotional processing such as
facial affect processing, and empathy [43–45], whereas the posterior part is involved in the
Table 2. Correlation between right AI volume and QLS Instrumental Role (IR) category score.
AI Volume / IR Score + Control variables Partial Correlation
#0 None 0.58***
#1 #0 + Education, VIQ, PIQ 0.64***
#2 #1 + Drug, Duration of illness 0.59**
#3 #2 + PANSS Positive 0.59**
#4 #3 + PANSS Negative 0.48*
Significant correlation at the
*** 0.001 level;
** 0.005 level; and
* 0.05 level (two-tailed).
doi:10.1371/journal.pone.0142018.t002
Fig 3. Partial mediation effect of negative symptoms on right anterior insula volume and QLS Instrumental Role score. Mediation analysis using
negative symptoms asmediator. a: coefficient for the association between right AI volume and negative symptoms; b: coefficient for the association
between negative symptoms and QLS Instrumental Role score; c: total effect from bivariate analysis; c0: direct effect frommediation analysis; rAI: right
anterior insula gray matter volume; IR: Instrumental Role QLS category score; Neg: PANSS negative symptom score.
doi:10.1371/journal.pone.0142018.g003
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encoding of multimodal sensory processing such as interoceptive awareness and somatosen-
sory processing [46]. Brain alterations in the AI may be linked to dysfunction in emotional pro-
cessing such as facial affect recognition and empathic ability, which underlie negative
symptoms [47, 48]. This in turn, is crucial for playing a sufficient and satisfied occupational
role as a member of the community [49], i.e., one aspect of objective QOL.
Mediation analysis showed that negative but not positive symptoms mediated the correla-
tion between right AI volume and IR score. A recent study reported a relationship between
negative symptoms and objective QOL in schizophrenia patients [50]. The same study also
suggested that negative symptoms have a greater impact on real-world functioning than posi-
tive symptoms. Our findings are in agreement with this. Although structural and functional
alterations in the insula are linked to positive symptoms in schizophrenia [51–53], recent
Fig 4. Nomediation effect of positive symptoms on right AI volume and QLS Instrumental Role score. Mediation analysis using positive
symptoms as the mediator. a: unstandardized regression coefficient for the association between right AI volume and positive symptoms; b: unstandardized
regression coefficient for the association between negative symptoms and QLS Instrumental Role score; c: total effect from bivariate analysis; c0: direct effect
frommediation analysis; rAI: right anterior insula gray matter volume; IR: Instrumental Role QLS category score; Pos: PANSS positive symptom score.
doi:10.1371/journal.pone.0142018.g004
Table 3. Correlations between QLS and JSQLS.
JSQLS Psychosocial JSQLS Motivation / energy JSQLS Symptoms / side-effects
QLS Intrapsychic foundations - 0.480** - 0.357* - 0.389*
QLS Interpersonal relations - 0.475** - 0.306 - 0.256
QLS Instrumental role - 0.236 - 0.123 - 0.089
QLS Common objects and activities - 0.403* - 0.330 - 0.390*
Significant correlation at the
** 0.01 level and
* 0.05(two-tailed).
doi:10.1371/journal.pone.0142018.t003
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studies on functional connectivity in schizophrenia suggest that AI dysfunction is related to
negative symptoms [54, 55]. These results support our finding of a significant correlation
between AI volume and negative symptoms.
The mediation model using positive symptoms as the mediator between AI and IR did not
fit the data. This indicates that positive symptoms have no mediator effect on the correlation.
This finding corresponds with previous studies, which report that the effect of negative symp-
toms on objective QOL and social functioning are more robust than those of positive symp-
toms [21, 50].
Correlation analyses demonstrated significant correlation between subscales of subjective
and objective QOL. However, although IR score significantly correlated with AI GM volume in
our study, it had no correlation with any subjective QOL subscale. Lack of correlation between
IR score and objective or subjective QOL subscores was also reported previously [13]. These
findings imply that at least in some part the objective and subjective QOL consists of different
factors, and that combination of both of QOLs is necessary to adequately evaluate the overall
picture of a patient's QOL.
In our previous study, we demonstrated correlation between subjective QOL and DLPFC
GM volume reduction, which was mediated by positive symptoms of schizophrenia [12].
Taken this together with the current results, it is suggested that subjective and objective QOL
in schizophrenia have different underlying brain factors, i.e., DLPFC and AI, respectively. In
addition, links between both aspects of QOL and brain alterations are mediated by distinct
clinical symptoms, i.e., positive and negative symptoms. This may explain the discrepancy
between subjective and objective QOL in schizophrenia.
There are several limitations to our study. First, because all the patients were on medication,
we cannot exclude the influence of adverse effects (e.g., tardive dyskinesia and extrapyramidal
symptoms) on objective QOL [6, 14]. Second, we did not detect any significant correlation
between regional brain volume and any other objective QOL subscale. This may be due to the
small sample size, which may have resulted in loss of statistical power to detect other brain
regions that correlated with each scale. In fact, with a more liberal threshold, we found correla-
tions between each of other subcategories and regional brain volume in orbitofrontal cortex,
insula, and anterior cingulate cortex. Finally, objective QOL can be affected by factors such as
socioeconomic status [56] and cognitive function [23, 57], which were not assessed in this
study. Thus, deliberate consideration is needed for generalization of our results.
In conclusion, we have demonstrated that the instrumental role domain of objective QOL
correlates with GM alterations in the right AI in schizophrenia, and that negative symptoms
play a crucial role in the relationship between objective QOL and regional brain alterations.
The findings suggest that the neural basis of objective QOL might topographically differ from
that of subjective QOL. Combining imaging techniques with psychosocial methods will help
elucidate the factors associated with QOL, an important outcome of schizophrenia treatment.
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